๐ฐ Beigene News
Page 22 - Beigene News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Beigene. Real-time updates on events, politics, business and more.
December 15, 2021
The biggest IPO on Star Market flopped after BeiGene shares slumped by as much as 19 per cent on the first day of trading in Shanghai. Concerns about US delisting and steep declines in its Hong Kong and Nasdaq-listed securities clouded its debut.
December 15, 2021
Authorisation is based on Phase 3 ASPEN head-to-head trial comparing BRUKINSA against ibrutinib BeiGene (NASDAQ: BGNE; HKEX: 06160) announced today that the United Kingdom (UK) Medicines and Healthcare
December 14, 2021
The U.S.-listed Chinese stocks with the most American ownership donโt include many of the big names familiar to Wall Street, according to Morgan Stanley.
December 14, 2021
The U.S.-listed Chinese stocks with the most American ownership donโt include many of the big names familiar to Wall Street, according to Morgan Stanley.
December 14, 2021
The U.S.-listed Chinese stocks with the most American ownership donโt include many of the big names familiar to Wall Street, according to Morgan Stanley.
December 14, 2021
The U.S.-listed Chinese stocks with the most American ownership donโt include many of the big names familiar to Wall Street, according to Morgan Stanley.
December 11, 2021
11.12.2021 - BeiGene (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable medicines, today presented additional safety and efficacy results from an ongoing Phase 2 trial evaluating BRUKINSA ... Seite 1
December 10, 2021
10.12.2021 - BeiGene (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced results from the RATIONALE ... Seite 1
December 10, 2021
In RATIONALE 309, tislelizumab in combination with chemotherapy significantly prolonged progression-free survival for patients, with survival benefit observed across patient subgroups The safety
December 3, 2021
BeiGene, Ltd. (NASDAQ:BGNE; HKEX:06160) and EUSA Pharma (UK), Ltd. today announced that the China National Medical Products Administration (NMPA) has approved SYLVANT(siltuximab for injection) for the